5 Largest Canadian Cannabis LPs - 13% This Week; -26% In Last 6 Weeks

Image source


To help you with your investment decisions, this article presents

  • the stock performance of each of the 5 largest Canadian cannabis licensed producers (LPs) in the munKNEE Canadian Cannabis LPs Index this week and in the last 6 weeks in descending order,
  • the average 12-month stock price targets (source) for each constituent according to the analysts that cover these companies,
  • the percentage change from today's price,
  • the consensus buy, hold and sell recommendations, and
  • the percentage chance of encountering financial distress over the next 2 years (source)

 

  1. Cronos (CRON): DOWN 11.1% this week and DOWN 22.5% in the last 6 weeks
    • 18 analysts have:
      • an average year-end price target of $1.99 representing
      • a 33.7% increase from the March 10th price of $1.93 and
      • a consensus BUY rating and, according to an analysis by macroaxis.com, has
      • a 3% chance of going through some form of financial distress in the next two years.
  2. Tilray (TLRY): DOWN 14.5% this week and DOWN 24.6% in the last 6 weeks
    • 22 analysts have:
      • an average year-end price target of $2.64 representing
      • a 9.1% increase from the March 10th price of $2.42 and
      • a consensus BUY rating and, according to an analysis by macroaxis.com, has
      • a 68% chance of going through some form of financial distress in the next two years.
  3. Aurora (ACB): DOWN 11.9% this week and DOWN 27.5% in the last 6 weeks
    • 14 analysts have:
      • an average year-end price target of $1.32 representing
      • a 44.6% increase from the March 10th price of $0.74 and
      • a consensus HOLD rating and, according to an analysis by macroaxis.com, has
      • a 78% chance of going through some form of financial distress in the next two years.
  4. OrganiGram (OGI): DOWN 16.5% this week and DOWN 28.3% in the last 6 weeks
    • 15 analysts have:
      • an average year-end price target of $1.50 representing
      • a 107.6% increase from the March 10th price of $0.66 and
      • a consensus BUY rating and, according to an analysis by macroaxis.com, has
      • a 49% chance of going through some form of financial distress in the next two years.
  5. Canopy Growth (CGC): DOWN 10.9% this week and DOWN 30.0% in the last 6 weeks
    • 23 analysts have:
      • an average year-end price target of $2.22 representing
      • a 4.9% increase from the March 10th price of $2.05 and
      • a consensus SELL rating and, according to an analysis by macroaxis.com, has
      • a 53% chance of going through some form of financial distress in the next two years.

More By This Author:

Ayr Wellness Q4 Financials: Operating Loss Increases; EBITDA Improves
MindMed: Researching LSD And MNMA To Treat Neurological Diseases
Trulieve Q4 Financials: Revenue Static; Net Loss Reduced By 33%

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with